Skip to main navigation Skip to search Skip to main content

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Murtant Acute Lymphoblastic Leukemia (ALL)

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date08/23/16 → 08/22/23

Funding

  • Children's Hospital of Philadelphia: $10,500.00